Skip to main content
Shandong Sito Bio-technology Co., Ltd. logo

Shandong Sito Bio-technology Co., Ltd. — Investor Relations & Filings

Ticker · 300583 ISIN · CNE100002F36 LEI · 836800ENMRCW06CD2U25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,388 across all filing types
Latest filing 2026-04-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300583

About Shandong Sito Bio-technology Co., Ltd.

https://www.sitobiotech.com

Shandong Sito Bio-technology Co., Ltd. specializes in the research, development, and production of steroid hormone intermediates and active pharmaceutical ingredients (APIs). The company utilizes biological fermentation technology to transform phytosterols into critical precursors, including 4-AD, ADD, and 9-OH-AD. These materials are fundamental components for the synthesis of glucocorticoids, sex hormones, and progestogens. By integrating microbial strain engineering with large-scale industrial fermentation, the company provides high-purity raw materials for global drug manufacturing. Its operations emphasize green chemistry and sustainable production methods, maintaining a comprehensive supply chain that spans from raw material processing to the delivery of specialized chemical intermediates.

Recent filings

Filing Released Lang Actions
关于公司及子公司向银行申请综合授信额度及提供担保的公告
Capital/Financing Update Classification · 90% confidence The document is a public announcement by a listed company regarding its plan to apply for bank credit facilities and to provide guarantees for its subsidiary. It outlines the credit limits, guarantee amounts, board resolution, and related financial details. This is clearly an update on the company’s financing activities, matching the “Capital/Financing Update” category.
2026-04-27 Chinese
关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice to convene the company’s 2025 Annual General Meeting, including meeting time, agenda items, voting procedures, proxy authorization forms, and attachments. It is sent to shareholders to provide information and solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-27 Chinese
关于2025年度会计师事务所履职情况的评估报告
Audit Report / Information Classification · 92% confidence The document is titled “关于会计师事务所2025年度履职情况的评估报告” (“Report on the evaluation of the accounting firm’s performance for 2025”). It details the engagement of the audit firm, its credentials, historical litigation and sanctions, scope of work performed, audit procedures applied, and the company’s assessment of the audit firm’s performance. This is a standalone audit‐related report (excluding a full Annual Report) focusing on applied accounting and audit performance. It therefore falls under Audit Report/Information (AR). FY 2025
2026-04-27 Chinese
2025年度非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is a standalone special audit report (“专项审计说明”) issued by an accounting firm regarding the 2025 non-operating funds occupation and related party transactions, including the auditor’s opinion and detailed schedules. It is not a full annual report, earnings release, or management presentation but a separate audit opinion and working paper supplement. This matches the definition of an Audit Report / Information (AR). FY 2025
2026-04-27 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 93% confidence The document is a public announcement by Shandong Xite Bio-Tech Co., Ltd. regarding the progress of its ongoing share repurchase program, including loan commitments and a repurchase loan contract. This is clearly a transaction in the company’s own shares (share buyback). Therefore, it belongs to the Transaction in Own Shares category.
2026-04-22 Chinese
关于归还闲置募集资金补充流动资金的公告
Regulatory Filings Classification · 82% confidence The document is a routine corporate announcement in Chinese disclosing the return of idle raised funds used to supplement working capital. It does not present financial results, management discussion, or an investor presentation, nor is it an AGM or voting result. It’s not a new capital raise or share issue, but rather a regulatory disclosure of fund usage/return. Therefore, it falls into the general “Regulatory Filings” fallback category (RNS).
2026-04-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.